Revenue vs Net income
Reported dollars from 10-Q / 10-K filings. Q4 bars are derived (annual less nine months) where the 10-K does not tag Q4 separately.
Margin trend
Gross, operating and net margin. Margins are derived from reported dollars.
Income statement
From 10-Q / 10-K XBRL. Values in reported dollars; EPS in $/share; share counts in shares.
| FY12 | FY13 | FY14 | FY15 | FY16 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $8.4B |
| YoY | — | — | — | — | — |
| Cost of goods sold | $2.3B | $2.2B | $2.2B | $2.2B | $2.4B |
| YoY | — | -7.4% | +1.7% | -1.7% | +11.6% |
| Gross profit | $4.9B | $5.0B | $5.2B | $5.3B | $6.0B |
| YoY | — | +1.4% | +4.0% | +2.6% | +12.4% |
| Research & development | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Selling, general & administrative | $2.5B | $2.7B | $2.9B | $2.9B | $3.1B |
| YoY | — | +5.5% | +8.5% | -1.0% | +7.9% |
| Operating income | $-3.9B | $120.0M | $-301.0M | $-283.0M | $447.0M |
| YoY | — | +103.1% | -350.8% | +6.0% | +258.0% |
| Pretax income | $-4.1B | $-223.0M | $-509.0M | $-650.0M | $177.0M |
| YoY | — | +94.6% | -128.3% | -27.7% | +127.2% |
| Income tax | $-39.0M | $-102.0M | $-390.0M | $-411.0M | $-170.0M |
| YoY | — | -161.5% | -282.4% | -5.4% | +58.6% |
| Net income | — | — | — | — | — |
| YoY | — | — | — | — | — |
| EPS — basic | $-2.89 | $-0.09 | $-0.09 | $-0.18 | $0.26 |
| YoY | — | +96.9% | +0.0% | -100.0% | +244.4% |
| EPS — diluted | $-2.89 | $-0.09 | $-0.09 | $-0.18 | $0.25 |
| YoY | — | +96.9% | +0.0% | -100.0% | +238.9% |
| Weighted shares — basic | 1.41B | 1.34B | 1.32B | 1.34B | 1.36B |
| Weighted shares — diluted | 1.41B | 1.34B | 1.32B | 1.34B | 1.38B |
Balance sheet
Point-in-time values at each quarter (or fiscal year) end.
| FY12 | FY13 | FY14 | FY15 | FY16 | |
|---|---|---|---|---|---|
| Cash & equivalents | $207.0M | $217.0M | $587.0M | $319.0M | $196.0M |
| YoY | — | +4.8% | +170.5% | -45.7% | -38.6% |
| Marketable securities (current) | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Inventory | $884.0M | $897.0M | $946.0M | $1.0B | $955.0M |
| YoY | — | +1.5% | +5.5% | +7.4% | -6.0% |
| Total current assets | $3.0B | $3.0B | $3.6B | $3.5B | $3.2B |
| YoY | — | -0.4% | +19.8% | -3.7% | -6.7% |
| Total assets | $17.2B | $16.6B | $17.0B | $18.1B | $18.1B |
| YoY | — | -3.4% | +2.7% | +6.5% | -0.2% |
| Total current liabilities | $1.8B | $1.8B | $2.8B | $2.4B | $3.6B |
| YoY | — | +2.9% | +56.0% | -14.6% | +47.6% |
| Total liabilities | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Total equity | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Shares outstanding | — | — | — | — | — |
| YoY | — | — | — | — | — |
Cash flow
Quarterly values derived from year-to-date filings (Q4 from the 10-K). Free cash flow = operating cash flow − capital expenditures.
| FY12 | FY13 | FY14 | FY15 | FY16 | |
|---|---|---|---|---|---|
| Operating cash flow | $1.3B | $1.1B | $1.3B | $691.0M | $1.2B |
| YoY | — | -13.3% | +14.3% | -45.5% | +71.1% |
| Capital expenditures | $226.0M | $245.0M | $259.0M | $247.0M | $376.0M |
| YoY | — | +8.4% | +5.7% | -4.6% | +52.2% |
| Free cash flow | $1.1B | $865.0M | $1.0B | $444.0M | $806.0M |
| YoY | — | -17.9% | +16.8% | -56.0% | +81.5% |
| Dividends paid | — | — | — | — | — |
| YoY | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| YoY | — | — | — | — | — |
Margins & ratios
Derived from the reported dollars above — no separate source.
| FY12 | FY13 | FY14 | FY15 | FY16 | |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 71.1% |
| Operating margin | — | — | — | — | 5.3% |
| Net margin | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | 9.6% |
| Effective tax rate | 0.9% | 45.7% | 76.6% | 63.2% | -96.0% |
| Current ratio | 1.71x | 1.65x | 1.27x | 1.43x | 0.90x |
| Total liabilities / equity | — | — | — | — | — |
Peer comparison — latest full year
Same sector (Health Care), sorted by revenue. All figures from the same EDGAR XBRL snapshot.
| Ticker | Revenue | Revenue YoY | Gross margin | Operating margin | Net margin | FCF margin |
|---|---|---|---|---|---|---|
| BSX FY16 · this stock | $8.4B | — | 71.1% | 5.3% | — | 9.6% |
| UNH FY25 | $447.6B | +11.8% | — | 4.2% | 2.7% | 3.6% |
| CVS FY25 | $402.1B | +7.8% | — | 1.2% | 0.4% | 1.9% |
| CI FY25 | $274.9B | +11.2% | — | 3.3% | — | — |
| ELV FY25 | $199.1B | +12.5% | — | 3.6% | 2.8% | 1.6% |
| JNJ FY25 | $94.2B | +6.0% | 67.9% | — | 28.5% | 20.9% |
| LLY FY25 | $65.2B | +44.7% | — | — | 31.7% | — |
| MRK FY25 | $65.0B | +1.3% | — | — | 28.1% | 19.0% |
| ABBV FY25 | $61.2B | +8.6% | — | 24.6% | 6.9% | 29.1% |
| BMY FY25 | $48.2B | -0.2% | — | — | 14.6% | 26.7% |
| TMO FY25 | $44.6B | +3.9% | — | 17.4% | 15.0% | 14.1% |
Source: SEC EDGAR XBRL company facts (10-Q / 10-K), snapshot generated 2026-11-03 for 218 tickers. Q4 values are derived as the 10-K annual less the first nine months, since Q4 is not separately tagged in company facts; cash-flow quarterly values are derived from year-to-date filings the same way. Free cash flow = operating cash flow − capital expenditures. Blank cells mean the filing does not report that line item under a standard US-GAAP tag — nothing is estimated or filled in. Descriptive research, not investment advice. How EarnIQ builds fundamentals.